Morphic’s $103.5 Million Initial Public Offering


Fenwick & West advised Morphic Holding on its IPO transaction.

Morphic Holding (MORF) is a biopharmaceutical company discovering and developing oral small-molecule integrin therapeutics.

Its initial public offering is 6.9 million shares at a price of $15 per share, raising gross proceeds of $103.5 million. ????

The underwriters on the Morphic offering are Jefferies LLC, Cowen and Company LLC, BMO Capital Markets Corp. and Wells Fargo Securities LLC.????

The Fenwick transaction team included corporate lawyers Robert Freedman (Picture), Effie Toshav, Julia Forbess, Alice Lin, Morgan McDonell, Emily Yi, Christian Olano and Ellen Welichko; executive compensation and employee benefits lawyers: Matt Cantor, Laura McIntyre, Corinne Nhaissi; intellectual property lawyers: Stefano Quintini and Amy Manning.??

Involved fees earner: Matthew Cantor – Fenwick & West LLP; Julia Forbess – Fenwick & West LLP; Robert Freedman – Fenwick & West LLP; Alice Lin – Fenwick & West LLP; Amy Manning – Fenwick & West LLP; Morgan McDonell – Fenwick & West LLP; Laura McIntyre – Fenwick & West LLP; Corinne Nhaissi – Fenwick & West LLP; Christian Olano – Fenwick & West LLP; Stefano Quintini – Fenwick & West LLP; Effie Toshav – Fenwick & West LLP; Emily Yi – Fenwick & West LLP;

Law Firms: Fenwick & West LLP;

Clients: Morphic Therapeutic;